Search Results - "BOLAND, Katja"

First‐in‐human study assessing safety, tolerability and pharmacokinetics of BI 409306, a selective phosphodiesterase 9A inhibitor, in healthy males by Moschetti, Viktoria, Boland, Katja, Feifel, Ulrich, Hoch, Anja, Zimdahl‐Gelling, Heike, Sand, Michael

“…Aims The aim of the present study was to investigate the safety, tolerability, dose proportionality and relative bioavailability of tablet and oral solution…”
Get full text

A phase I, randomized, proof‐of‐clinical‐mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers by Boland, Katja, Moschetti, Viktoria, Dansirikul, Chantaratsamon, Pichereau, Solen, Gheyle, Lien, Runge, Frank, Zimdahl‐Gelling, Heike, Sand, Michael

“…Objective Cyclic guanosine monophosphate (cGMP)‐specific phosphodiesterase (PDE) inhibitors are hypothesized to improve cognition in schizophrenia and…”
Get full text

The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: Overview of three Phase I randomised trials in healthy volunteers by Moschetti, Viktoria, Kim, Maria, Sand, Michael, Wunderlich, Glen, Andersen, Grit, Feifel, Ulrich, Jang, In-Jin, Timmer, Wolfgang, Rosenbrock, Holger, Boland, Katja

“…Safety, tolerability and pharmacokinetics of BI 409306, a potent and selective phosphodiesterase 9A inhibitor, were assessed in healthy subjects in three Phase…”
Get full text

Population Pharmacokinetic/Pharmacodynamic Model for the Sedative Effects of Flibanserin in Healthy Volunteers by Trocóniz, Iñaki F., Boland, Katja, Staab, Alexander

“…ABSTRACT Purpose Flibanserin is being developed for treating hypoactive sexual desire disorder in women; the main side effect is sedation. The analysis…”
Get full text

Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple-rising doses of bi409306 film-coated tablets given orally once- or twice-daily for 14 days in young and elderly healthy volunteers by Moschetti, Viktoria, Boland, Katja, Hoch, Anja, Timmer, Wolfgang, Zimdahl-Gelling, Heike, Borta, Andreas, Sand, Michael

Get full text

P1‐295: Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple‐rising doses of bi409306 film‐coated tablets given orally once‐ or twice‐daily for 14 days in young and elderly healthy volunteers by Moschetti, Viktoria, Boland, Katja, Hoch, Anja, Timmer, Wolfgang, Zimdahl-Gelling, Heike, Borta, Andreas, Sand, Michael

Get full text

Potential Cost-effectiveness of Therapeutic Drug Monitoring for Depressed Patients Treated With Citalopram by OSTAD HAJI, Elnaz, MANN, Klaus, DRAGICEVIC, Aleksandra, MÜLLER, Matthias J, BOLAND, Katja, RAO, Marie-Luise, FRIC, Miriam, LAUX, Gerd, HIEMKE, Christoph

“…For patients treated with citalopram, it was recently shown that serum concentrations above 50 ng/mL on day 7 of treatment are associated with an improved…”
Get full text

Association Between Citalopram Serum Levels and Clinical Improvement of Patients With Major Depression by OSTAD HAJI, Elnaz, TADIC, André, WAGNER, Stefanie, DRAGICEVIC, Aleksandra, MÜLLER, Matthias J, BOLAND, Katja, RAO, Marie-Luise, FRIC, Miriam, LAUX, Gerd, HIEMKE, Christoph

“…Imaging studies have shown that serum concentrations of the selective serotonin reuptake inhibitor citalopram correlate with serotonin transporter (5-HTT)…”
Get full text

Pooled analysis of tiotropium Respimat® pharmacokinetics in cystic fibrosis by Sharma, Ashish, Geller, David E, Moroni-Zentgraf, Petra, Kattenbeck, Sabine, Schmid, Marion, Boland, Katja, Rapp, Barbara, Konstan, Michael W, Ratjen, Felix, Elborn, J. Stuart, Koker, Paul

“…Abstract Tiotropium is the first bronchodilator to be studied systematically in cystic fibrosis (CF). We investigated whether any intrinsic or extrinsic…”
Get full text